Evidence map›Paper›PMID 28138763›Full record

ReviewDer Internist2017

[Haemoptysis : Intensive care management of pulmonary hemorrhage].

J H Ficker, W M Brückl, J Suc, A Geise

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

J H FickerKlinik für Innere Medizin 3, Schwerpunkt Pneumologie, Allergologie, Schlafmedizin, Intensivmedizin, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland. ficker@klinikum-nuernberg.de.
W M BrücklKlinik für Innere Medizin 3, Schwerpunkt Pneumologie, Allergologie, Schlafmedizin, Intensivmedizin, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland.
J SucMedizinische Klinik 2, Schwerpunkt Geriatrie, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität Nürnberg, Nürnberg, Deutschland.
A GeiseKlinik für Innere Medizin 3, Schwerpunkt Pneumologie, Allergologie, Schlafmedizin, Intensivmedizin, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland.
Paracelsus Medizinische Privatuniversität · DENuremberg Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a wide spectrum of severities in patients with pulmonary bleeding with a range from mild haemoptysis to severe bleeding with an acute risk of asphyxiation. For the management of acute pulmonary haemorrhage, it is essential to identify the underlying cause in order to initiate a target-oriented or causal therapy. The most common causes of localized pulmonary bleeding are lung cancer as well as infections, anticoagulant therapy or bronchiectasis. Diffuse alveolar haemorrhage is mostly due to pulmonary vasculitis or connective tissue disease, but may also occur in pulmonary metastasis, congestive heart failure, coagulation disorders and from many other causes. In a case of severe pulmonary bleeding it is essential to secure the airways and ensure sufficient ventilation, i. e. by intubation with a double-lumen endotracheal tube and by appropriate positioning of the patient. Stabilizing haemodynamics is crucial. Simultaneously basic diagnostic measures, i. e. appropriate laboratory tests, chest X‑ray, computed tomography scan of the chest and bronchoscopy, are performed. Localized pulmonary bleeding usually requires local treatment, like bronchoscopic therapy, bronchial artery embolization or surgery. Diffuse alveolar haemorrhage must be treated systemically, i. e. by immunosuppressive therapy in cases of vasculitis or by medical treatment of coagulation disorders. Even with optimal interdisciplinary management the in-hospital mortality of severe pulmonary bleeding remains high. There is a significant risk of recurrent bleeding depending on the cause of haemorrhage. In patients with "cryptogenic" haemoptysis there is an increased rate of lung cancer within the following years and follow-up of these patients is recommended.

Indexed as

BronchoscopyCritical CareEmbolization, TherapeuticHemoptysisHemorrhageHumansLung DiseasesRecurrenceBronchiectasisBronchoscopyEmbolization, therapeuticHemoptysisLung neoplasms

Identifiers

PMID28138763
OpenAlexW2580911448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.